Molecular Pathogenesis of Transplacentally Induced Mouse Lung Tumors

References

• Parker S L, Tong T, Bolden S, Wingo P A. Cancer Statistics, 1997. CA-Cancer J Clin. 1997; 47: 5–27
   PubMed Web of Science ®Google Scholar
• Rice J M. Perinatal period and pregnancy: intervals of high risk for chemical carcinogens. Environ Health Perspect. 1979; 29: 23–27
   PubMed Web of Science ®Google Scholar
• Miller M S, Jones A B, Anderson L M. The formation of 3-methylcholanthrene-initiated lung tumors correlates with induction of cytochrome CYPIA1 by the carcinogen in fetal but not adult mice. Toxicol Appl Pharmacol. 1990; 104: 235–245
   PubMed Web of Science ®Google Scholar
• Miller M S. Transplacental lung carcinogenesis: a pharmacogenetic mouse model for the modulatory role of cytochrome P450 1AI on lung cancer. Chem Res Toxicol. 1994; 7: 471–481
   PubMed Web of Science ®Google Scholar
• Kellermann G, Shaw C, Luyten-Kellermann M. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. New Engl J Med. 1973; 189: 934–937
   Google Scholar
• Kouri R E, McKinney C E, Slomiany D J, Snodgrass D R, Wray N P, McLemore T L. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 1982; 42: 5030–5037
   PubMed Web of Science ®Google Scholar
• Petruzzelli S, Camus A -M, Carrozzi L, et al. Long-lasting effects of tobacco smoking on pulmonary drug-metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res. 1988; 48: 4695–4700
   PubMed Web of Science ®Google Scholar
• McLemore T L, Adelberg S, Liu M C, et al. Expression of CYPIA1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst. 1990; 82: 1333–1339
   PubMed Web of Science ®Google Scholar
• Rojas M, Camus A -M, Alexandrov K, et al. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis. 1992; 13: 929–933
   PubMed Web of Science ®Google Scholar
• Stjernfeldt M, Berglund K, Lindsten J, Ludvigsson J. Maternal smoking during pregnancy and risk of childhood cancer. Lancet. 1986; 1350–1352
   PubMed Web of Science ®Google Scholar
• Bunin G R, Kramer S, Marrero O, Meadows A T. Gestational risk factors for Wilms' tumor: results of a case-control study. Cancer Res. 1987; 47: 2972–2977
   PubMed Web of Science ®Google Scholar
• Sandler D P, Everson R B, Wilcox A J, Browder J P. Cancer risk in adulthood from early life exposure to parents' smoking. Am J Public Health. 1985; 75: 487–492
   PubMed Web of Science ®Google Scholar
• John E M, Savitz D A, Sandler D P. Prenatal exposure to parents' smoking and childhood cancer. Am J Epidemiol. 1991; 133: 123–132
   PubMed Web of Science ®Google Scholar
• Hansen C, Sørensen L D, Asmussen I, Autrup H. Transplacental exposure to tobacco smoke in human-adduct formation in placenta and umbilical cord blood vessels. Teratogenesis, Carcinog Mutagen. 1992; 12: 51–60
   PubMedGoogle Scholar
• Manchester D K, Weston A, Choi J -S, et al. Detection of benzo[a]pyrene diol epoxide-DNA adducts in human placenta. Proc Natl Acad Sci USA. 1988; 85: 9243–9247
   PubMed Web of Science ®Google Scholar
• Manchester D K, Bowman E D, Parker N B, Caporaso N E, Weston A. Determinants of polycyclic aromatic hydrocarbon-DNA adducts in human placenta. Cancer Res. 1992; 52: 1499–1503
   PubMed Web of Science ®Google Scholar
• Whyatt R M, Garte S J, Cosma G, et al. CYP1A1 messenger RNA levels in placental tissue as a bio-marker of environmental exposure. Cancer Epidemiol Biomarkers Prev. 1995; 4: 147–153
   PubMed Web of Science ®Google Scholar
• Malkinson A M. The genetic basis of susceptibility to lung tumors in mice. Toxicology. 1989; 54: 241–271
   PubMed Web of Science ®Google Scholar
• Witschi H. Modulation of lung tumor development in rats, hamsters and mice. Prog Exp Tumor Res. 1991; 33: 132–153
   PubMed Web of Science ®Google Scholar
• Malkinson A M. Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res. 1992; 52(S)2670–2676s
   Google Scholar
• Thomas P E, Kouri R E, Hutton J J. The genetics of aryl hydrocarbon hydroxylase induction in mice: a single gene difference between C57BL/6J and DBA/2J. Biochem Genet. 1972; 6: 157–168
   PubMed Web of Science ®Google Scholar
• Gielen J E, Goujon F M, Nebert D W. Genetic regulation of aryl hydrocarbon hydroxylase induction: simple Mendelian expression in mouse tissues in vivo. J Biol Chem. 1972; 247: 1125–1137
   PubMed Web of Science ®Google Scholar
• Okey A B, Vella L M, Harper P A. Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol Pharmacol. 1989; 35: 823–830
   PubMed Web of Science ®Google Scholar
• Chang C -Y, Smith D R, Prasad V S, Sidman C L, Nebert D W, Puga A. Ten nucleotide differences, five of which cause amino acid changes, are associated with the Ah receptor locus polymorphism of C57BL/6 and DBA/2 mice. Pharmacogenetics. 1993; 3: 312–321
   PubMedGoogle Scholar
• Miller M S, Juchau M R, Guengerich F P, Nebert D W, Raucy J L. Drug metabolic enzymes in developmental toxicology. Fundam Appl Toxicol. 1996; 34: 165–175
   PubMedGoogle Scholar
• Anderson L M, Jones A B, Riggs C W, Ohshima M. Fetal mouse susceptibility to transplacental lung and liver carcinogenesis by 3-methylcholanthrene: positive correlation with responsiveness to inducers of aromatic hydrocarbon metabolism. Carcinogenesis. 1985; 6: 1389–1393
   PubMed Web of Science ®Google Scholar
• Miller M S, Jones A B, Chauhan D P, Park S S, Anderson L M. Differential induction of fetal mouse liver and lung cytochromes P-450 by β-naphthoflavone and 3-methylcholanthrene. Carcinogenesis. 1989; 10: 875–883
   PubMed Web of Science ®Google Scholar
• Miller M S, Jones A B, Chauhan D P, Anderson L M. Role of the maternal environment in determining susceptibility to transplacentally induced chemical carcinogenesis in mouse fetuses. Carcinogenesis. 1990; 11: 1979–1984
   PubMed Web of Science ®Google Scholar
• Wessner L L, Fan M, Schaeffer D O, McEntee M F, Miller M S. Mouse lung tumors exhibit specific Ki-ras mutations following transplacental exposure to 3-methylcholanthrene. Carcinogenesis. 1996; 17: 1519–1526
   PubMed Web of Science ®Google Scholar
• Rehm S, Ward J M, Have-Opbroek A AWT, et al. Mouse papillary lung tumors transplacentally induced by N-nitrosoethylurea: evidence for alveolar type II cell origin by comparative light microscopic, ultrastructural, and immunohistochemical studies. Cancer Res. 1988; 48: 148–160
   PubMed Web of Science ®Google Scholar
• Faccini J M, Abbott D P, Paulus G JJ. Mouse Histopathology: A Glossary for Use in Toxicity and Carcinogenicity Studies. Elsevier Scientific, New York 1990; 48–62
   Google Scholar
• Conti C J. Mutations of genes of the ras family in human and experimental tumors. Comparative Molecular Carcinogenesis, A JP Klein-Szanto, M W Anderson, J C Barrett, T J Slaga. Wiley-Liss, New York 1992; 357–378
   Google Scholar
• Carbone D P, Minna J D. The molecular genetics of lung cancer. Advances in Internal Medicine, G H Stollerman, J T LaMont, J J Leonard, M D Siperstein. Mosby Year Book, St. Louis 1992; 37: 153–171
   Google Scholar
• Reynolds S H, Wiest J S, Devereux T R, Anderson M W, You M. Protooncogene activation in spontaneously occurring and chemically induced rodent and human lung tumors. Comparative Molecular Carcinogenesis, A JP Klein-Szanto, M W Anderson, J C Barrett, T J Slaga. Wiley-Liss, New York 1992; 303–320; 5738–5741
   Google Scholar
• Mitsudomi T, Viallet J, Mulshine J L, Linnoila R I, Minna J D, Gazdar A F. Mutations of ras genes distinguish a subset of non-small cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991; 6: 1353–1362
   PubMed Web of Science ®Google Scholar
• Slebos R JC, Hruban R H, Dalesio O, Mooi W J, Offerhaus G JA, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 1991; 83: 1024–1027
   PubMed Web of Science ®Google Scholar
• Mills N E, Fishman C L, Rom W N, Dubin N, Jacobson D R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995; 55: 1444–1447
   PubMed Web of Science ®Google Scholar
• Leone-Kabler S, Wessner L L, McEntee M F, D'Agostino R B, Miller M S. Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors. Carcinogenesis. 1997; 18: 1163–1168
   PubMed Web of Science ®Google Scholar
• Miller M S, Baxter J L, Moore J W, Lewis J D, Schuller H M. Molecular characterization of neuroendocrine lung tumors induced in hamsters by treatment with nitrosamines and hyperoxia. Int J Oncol. 1994; 4: 5–12
   PubMed Web of Science ®Google Scholar
• Wang X, Witschi H. Mutations of the Ki-ras protooncogene in 3-methylcholanthrene and urethan-induced and butylated hydroxytoluene-promoted lung tumors of strain A/J and SWR mice. Cancer Lett. 1995; 91: 33–39
   PubMed Web of Science ®Google Scholar
• Osborne M R, Brookes P, Lee H, Harvey R G. The reaction of a 3-methylcholanthrene diol epoxide with DNA in relation to the binding of 3-methylcholanthrene to the DNA of mammalian cells. Carcinogenesis. 1986; 7: 1345–1350
   PubMed Web of Science ®Google Scholar
• Nuzum E O, Malkinson A M, Beer D G. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol Carcinogen. 1990; 3: 287–295
   PubMed Web of Science ®Google Scholar
• Li E E, Heflich R H, Bucci T J, Manjanatha M G, Blaydes B S, Delclos K B. Relationships of DNA adduct formation, K-ras activating mutations and tumorigenic activities of 6-nitrochrysene and its metabolites in the lungs of CD-1 mice. Carcinogenesis. 1994; 15: 1377–1385
   PubMed Web of Science ®Google Scholar
• Finkelstein S D, Sayegh R, Bakker A, Swalsky P. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg. 1993; 128: 526–532
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, van de Wetering M L, Mooi W J, Evers S G, van Zandwijk N, Bos J L. Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. New Engl J Med. 1987; 317: 929–935
   PubMed Web of Science ®Google Scholar
• Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 1993; 8: 2407–2412; 411–418
   PubMed Web of Science ®Google Scholar
• Li Z -H, Zheng J, Weiss L M, Shibata D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol. 1994; 144: 303–309
   PubMed Web of Science ®Google Scholar
• Keohavong P, DeMichele M AA, Melacrinos A C, Landreneau R J, Weyant R J, Siegfried J M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res. 1996; 2: 411–418
   PubMed Web of Science ®Google Scholar
• Westra W H, Baas I O, Hruban R H, et al. K-ras activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996; 56: 2224–2228
   PubMed Web of Science ®Google Scholar
• Rosell R, Monzo M, Pifarre A, et al. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res. 1996; 2: 1083–1086
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Slebos R JC, Boot A JM, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988; 48: 5738–5741
   PubMed Web of Science ®Google Scholar
• Greenblatt M S, Bennet W P, Hollstein M, Harris C C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855–4878
   PubMed Web of Science ®Google Scholar
• Levine A J. p53, the cellular gatekeeper for growth and cell division. Cell. 1997; 88: 323–331
   PubMed Web of Science ®Google Scholar
• Paulovich A G, Toczyski D P, Hartwell L H. When checkpoints fail. Cell. 1997; 88: 315–321
   PubMed Web of Science ®Google Scholar
• Weinberg R A. The retinoblastoma protein and cell cycle control. Cell. 1995; 81: 323–330
   PubMed Web of Science ®Google Scholar
• Sherr C J. Cancer cell cycles. Science 1996; 274: 1672–1677
   PubMed Web of Science ®Google Scholar
• Serrano M, Hannon G J, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704–707
   PubMed Web of Science ®Google Scholar
• Jin X, Nguyen D, Zhang W -W, Kyritsis A P, Roth J A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. 1995; 55: 3250–3253
   PubMed Web of Science ®Google Scholar
• Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375: 503–506
   PubMed Web of Science ®Google Scholar
• Medema R H, Herrera R E, Lam F, Weinberg R A. Growth suppression by p16Ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA. 1995; 92: 6289–6293
   PubMed Web of Science ®Google Scholar
• Khleif S N, DeGregori J, Yee C L, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA. 1996; 93: 4350–4354
   PubMed Web of Science ®Google Scholar
• Shapiro G I, Edwards C D, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4a expression in primary lung cancers and cell lines. Cancer Res. 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho R A. Role of the INK4a locus in tumor suppression and cell mortality. 1996; 85: 27–37, Cell.
   Google Scholar
• Kratzke R A, Greatens T M, Rubins J B, et al. Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res. 1996; 56: 3415–3420
   PubMed Web of Science ®Google Scholar
• Otterson G A, Kratzke R A, Coxon A, Kim Y W, Kaye F J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 1994; 9: 3375–3378
   PubMed Web of Science ®Google Scholar
• Rollins L A, Kabler-Leone S, O'Sullivan M G, Miller M S. Role of tumor suppressor genes in transplacental lung carcinogenesis. Molec Carcinogenesis. 1998; 20: 177–184
   Google Scholar
• Beenken S W, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res. 1991; 19: 4747–4752
   PubMed Web of Science ®Google Scholar
• Quelle D E, Ashmun R A, Hannon G J, et al. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene. 1995; 11: 635–645
   PubMed Web of Science ®Google Scholar
• Herzog C R, Soloff E V, McDoniels A L, et al. Homozygous codeletion and differential decreased expression of p15INK4b p16INK4a-α and p16INK4a-β in mouse lung tumor cells. Oncogene. 1996; 13: 1885–1891
   PubMed Web of Science ®Google Scholar
• Hegi M E, Devereux T R, Dietrich W F, et al. Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res. 1994; 54: 6257–6264
   PubMed Web of Science ®Google Scholar
• Belinsky S A, Swafford D S, Middleton S K, Kennedy C H, Tesfaigzi J. Deletion and differential expression of p16INK4a in mouse lung tumors. Carcinogenesis. 1997; 18: 115–120
   PubMed Web of Science ®Google Scholar
• Sabourin C LK, Wang Q S, Herzog C R, et al. Retinoblastoma and p16INK4a alterations in 4- (methylnitrosamino)-1- (3-pyridyl)-1-butanone-induced mouse lung tumorigenesis. Proc Am Assoc Cancer Res. 1997; 38: 3135
   Google Scholar
• Re F C, Manenti G, Borrello M G, et al. Multiple molecular alterations in mouse lung tumors. Mol Carcinog. 1992; 5: 155–160
   PubMed Web of Science ®Google Scholar
• Ryan J, Barker P E, Nesbitt M N, Ruddle F H. KRAS2 as a genetic marker for lung tumor susceptibility in inbred mice. J Natl Cancer Inst. 1987; 79: 1351–1357
   PubMed Web of Science ®Google Scholar
• Donehower L A, Harvey M, Slagle B L, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–221
   PubMed Web of Science ®Google Scholar
• Purdie C A, Harrison D J, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 1994; 9: 603–609
   PubMed Web of Science ®Google Scholar
• Hegi M E, Söderkvist P, Foley J F, et al. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis. 1993; 14: 803–810
   PubMed Web of Science ®Google Scholar
• Horio Y, Chen A, Rice P, Roth J A, Malkinson A M, Schrump D S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol Carcinog. 1996; 17: 217–223
   PubMed Web of Science ®Google Scholar
• Okamoto A, Demetrick D J, Spillare E A, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 1994; 91: 11045–11049
   PubMed Web of Science ®Google Scholar
• Serrano M, Lin A W, McCurrach M E, Beach D, Lowe S W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997; 88: 593–602
   PubMed Web of Science ®Google Scholar
• Fan J, Bertino J R. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene. 1997; 14: 2595–2607
   PubMed Web of Science ®Google Scholar